Chronic lymphocytic leukemia (CLL) is a B-cell malignancy, which is associated with
profound alterations and defects in the immune system and a prevalent dependency on the …

Bruton´ s tyrosine kinase (BTK) inhibitor (BTKi) s block the B-cell receptor (BCR) signaling
cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a wide range of
tumor-induced alterations, which affect both the innate and adaptive arms of the immune …

Chronic lymphocytic leukemia (CLL) is associated with substantial alterations in T-cell
composition and function. However, the role of T-cells in CLL remains largely controversial …

B-cell receptor (BCR) signaling and tumor–microenvironment crosstalk both drive chronic
lymphocytic leukemia (CLL) pathogenesis. Within the microenvironment, tumor cells shape …

Risk of serious infection among individuals with and without low count monoclonal B-cell
lymphocytosis (MBL) | Leukemia Skip to main content Thank you for visiting nature.com. You …

Targeting B-cell receptor signalling using Bruton tyrosine kinase (BTK) inhibitors (BTKis) has
become a highly successful treatment modality for B-cell malignancies, especially for …

The term monoclonal B-cell lymphocytosis (MBL) describes the presence of a clonal B cell
population with a count of less than 5× 109/L and no symptoms or signs of disease. Based …

Purpose: Using next-generation sequencing (NGS), we recently documented T-cell
oligoclonality in treatment-naïve chronic lymphocytic leukemia (CLL), with evidence …

Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction.
CLL cells affect the phenotype and function of the entire spectrum of innate and adaptive …